Secure patient access

ISPOR 2019 Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 5 markets?


Extremely high-cost CAR-T immunotherapies, specifically Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel), are becoming more widely available worldwide despite the limited clinical data available at launch.

This study investigates whether the evidence for Kymriah and Yescarta for the diffuse large B-cell lymphoma (DLBCL) indication was sufficient to secure a positive outcome from HTA bodies in Europe and the USA, and how gaps in the current evidence are linked to access restrictions and mitigation strategies.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.